ACLY and esophageal squamous cell carcinoma: In conclusion, our preliminary results suggest that ACLY inhibitor BMS‐303141 suppresses cell proliferation, migration, invasion, lipid synthesis and the growth of xenografted tumour in ESCC cells, whereas ACLY overexpression displays the opposite effects (Figure 10).